Strasbourg, France, March 3, 2020 – Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCR) in neurology, immune-oncology and rare diseases, announces today its acquisition of all shares in PC SAS (Prestwick Chemical) and Neurofit SAS (Neurofit), two former subsidiaries of Bionomics Ltd, an Australian biopharmaceutical company. By absorbing their liabilities, this acquisition constitutes an accounting neutral operation for Domain, without initial investment.
These acquisitions constitute a key step towards completing the company’s four-year business plan, ensuring the expansion of Domain’s portfolio of GPCR proprietary programs. With the additional resources and expertise, Domain will also be able to enter into larger collaborations with pharma partners and support its asset-centric affiliates.
In acquiring Prestwick Chemical, Domain will double its medicinal chemistry resources. Whilst pursuing the commercialization of renowned libraries, Prestwick Chemical will significantly contribute to increasing Domain’s capacity in medicinal chemistry for both internal programs and collaboration with pharma partners.
Neurofit will pursue its service-based activities in parallel with supplying Domain with a valuable animal pharmacology platform for neurological diseases, giving the company the opportunity to develop novel in vivo pharmacological axes.
“These acquisition opportunities perfectly match Domain’s need to strengthen its core scientific capabilities in order to pursue its growth in the coming years,” said Pascal Neuville, CEO, Domain Therapeutics. “The addition of these new capabilities will significantly streamline the expansion of our project portfolio and reinforce our partnering capacity.”
About G Protein-Coupled Receptors
GPCRs belong to the family of membrane receptors and constitute one of the main classes of therapeutic targets for many indications. The binding of a hormone or a specific ligand to a receptor’s binding site activates one or several pathways for intracellular signaling. This enables the cell to provide an adapted response to the change in its environment. The drugs that target GPCRs represent around 30% of all treatments on the market, but only address 28% of the GPCRs. Thus, GPCRs remain largely underexploited to date. Domain Therapeutics proposes novel drug candidates for the remaining 70%, thanks to its unique drug discovery engine using technologies such as bioSens-All™.
About Neurofit SAS
Neurofit is a preclinical platform based on animal models, specializing in the evaluation of new chemical entities and new active pharmaceutical ingredients for the treatment of nervous system disorders. Neurofit offers a comprehensive list of validated methods and disease models for drug efficacy and screening. Its objective is to accelerate drug development projects from worldwide partners – including leading biopharmaceutical companies in Europe, the US and Japan – ranging from large pharma to startups.
About Prestwick Chemical SAS
Prestwick Chemical is a French contract research organization, offering medicinal chemistry services (from Hit Discovery to Pre-clinical Candidate) as well as innovative smart compound collections dedicated to screening. The company’s team of medicinal chemists develops innovative medicinal chemistry strategies tailored to partners’ needs and offers a complete coverage of early drug discovery steps: virtual screening, hit identification/hit series validation, hit to lead and lead optimization. This expertise has been rewarded with an outstanding track record of achievements. Prestwick has a portfolio of smart libraries designed to ensure maximum chemical diversity with the possibility of accessing new Intellectual Property.
About Domain Therapeutics
Domain Therapeutics is a biopharmaceutical company dedicated to the discovery and development of new drug candidates targeting transmembrane receptors, in particular, G Protein-Coupled Receptors (GPCRs), one of the most important classes of drug targets. Domain identifies and develops candidates (allosteric modulators and biased ligands) through its innovative approach and technologies. Domain enters into collaboration with pharma companies for the discovery of new treatments and creates asset-centric vehicles for the development of its internal pipeline of drug candidates for central nervous system disorders, cancer and rare diseases. These asset-centric companies develop drug candidates up to clinical proof-of-concept and exit is through a trade sale.